2nd Circ. Won't Revive Elan, Pfizer Investor Row
By Sindhu Sundar ( February 1, 2013, 9:12 PM EST) -- The Second Circuit on Friday declined to revive a proposed securities class action against drugmakers Elan Corp. PLC and Pfizer Inc. over allegedly misleading statements in a press release about the clinical trial results of an Alzheimer's disease drug. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.